Overview

* Danaher ( DHR ) Q3 revenue up 4.5% yr/yr to $6.1 bln, beating analysts' expectations

* Adjusted EPS for Q3 at $1.89, exceeding expectations

* Company attributes growth to bioprocessing and higher-than-expected respiratory revenue at Cepheid

Outlook

* Danaher ( DHR ) maintains full-year adjusted EPS guidance of $7.70 to $7.80

* Company expects low-single digit core revenue growth for 2025

* Danaher anticipates 2.5% sales increase from currency impact in Q4 2025

Result Drivers

* BIOPROCESSING MOMENTUM - Co cites strong performance in bioprocessing as a key driver of Q3 results

* RESPIRATORY REVENUE - Higher-than-expected respiratory revenue at Cepheid contributed to exceeding expectations

* DBS EXECUTION - Co attributes exceeding expectations to DBS-driven execution

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Beat $6.10 $6 bln

Revenue bln (18

Analysts

)

Q3 Beat $1.89 $1.72

Adjusted (19

EPS Analysts

)

Q3 EPS $1.27

Q3 $1.70

Operatin bln

g Cash

Flow

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 22 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

* Wall Street's median 12-month price target for Danaher Corp ( DHR ) is $240.00, about 13.2% above its October 20 closing price of $208.39

* The stock recently traded at 25 times the next 12-month earnings vs. a P/E of 24 three months ago

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)